Paragon Bioservices Revenue and Competitors
Estimated Revenue & Valuation
- Paragon Bioservices's estimated annual revenue is currently $24.3M per year.
- Paragon Bioservices received $5.0M in venture funding in August 2018.
- Paragon Bioservices's estimated revenue per employee is $155,000
- Paragon Bioservices's total funding is $20M.
- Paragon Bioservices has 157 Employees.
- Paragon Bioservices grew their employee count by -21% last year.
Paragon Bioservices Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Paragon Bioservices?
Paragon Bioservices is an industry-leading, private-equity backed contract development and manufacturing organization (CDMO) whose focus is the development and manufacturing of cutting-edge biopharmaceuticals. Paragon's aim is to build strong client partnerships with the world's best biotech and pharma companies, focusing on transformative technologies, including gene therapies (AAV), next-generation vaccines, oncology immunotherapies (oncolytic viruses and CAR-T cell therapies), therapeutic protein, and other complex biologics.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
Paragon Bioservices News
Paragon Bioservices, Inc., a Baltimore, MD-based contract research and manufacturing organization that aims to accelerate the development and manufacturing of biopharmaceuticals and vaccines, raised $13m in Series A financing. The round was led by NewSpring Capital and Camden Partners. In conju ...
The company also just brought on a new COO, Pete Buzy, to its leadership team. The guy was formerly CFO of Martek Biosciences for 13 years, and helped orchestrate its $1.1 billion sale to Royal DSM. “Market factors, including the consolidation of the pharmaceutical industry and the growth of vi ...
Paragon Bioservices, the leading private equity-backed biologics contract development and manufacturing organization (CDMO) with proven expertise in gene therapy and next-generation vaccines, announces today the promotion of key personnel and the addition of two industry veterans to its leadersh ...
Just this year, Catalent bought out California-based Paragon Bioservices? and Thermo Fisher Scientific acquired Brammer Bio?, located in ...
By April of 2019, Catalent had agreed to a $1.2 billion acquisition of gene therapy developer Paragon Bioservices. And most recently, the ...
Why Paragon Bioservices' $1.2B acquisition deal matters to Baltimore ... it had agreed to acquire Paragon Bioservices in a $1.2 billion deal.
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Paragon Bioservices Funding